Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:25:27.978Z.
Consensus retrieved: 2026-10-06T08:46:19.947Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:25:27.978Z.
Quote observation: 2026-10-06T18:25:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9f7ef7d03019e78f4201474ef0c74f9c2a497de6c29d743f28e52983e243880
Forward PE Ratio (N/A) = Dated Quote Price ($27.71) / Consensus Forward EPS ($-1.51)
FORWARD PE RATIO
N/A
Amylyx Pharmaceuticals, Inc.
Market Cap
$3.08B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.08B | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.10B | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.03B | 48.73 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $2.99B | N/A |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.21B | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.85B | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.33B | N/A |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.33B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.80B | 55.14 |
| AtriCure, Inc. (ATRC)vs › | $2.78B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $27.71, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.51 | $-1.60 – $-1.45 | 7 | n/m |
| 2027-12-31 | $-1.18 | $-1.38 – $-1.01 | 7 | n/m |
| 2028-12-31 | $-0.26 | $-0.95 – $0.25 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
